U.S. Arthritis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

U.S. Arthritis Market Segmentation, By Type (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Spondyloarthritis, Juvenile Idiopathic Arthritis (JIA), and Others), Product (Treatment and Diagnosis), Drug Type (Branded and Generics), Medication Type (Prescription Drugs and Over-The-Counter Drugs), Route of Administration (Parenteral, Oral, and Others), Population Type (Geriatrics, Adults, and Children), End User (Hospital, Specialty Centers, Homecare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)- Industry Trends and Forecast to 2032

U.S. Arthritis Market Size

• The U.S. arthritis market size was valued at USD 41.77 billion in 2024 and is expected to reach USD 90.86 billion by 2032, at a CAGR of 10.20% during the forecast period
• The market growth is largely driven by the increasing prevalence of arthritis-related conditions, such as osteoarthritis and rheumatoid arthritis, especially among the aging population, along with growing awareness and access to advanced therapeutic options
• Furthermore, rising demand for personalized treatment, including biologics and disease-modifying antirheumatic drugs (DMARDs), is positioning arthritis care as a priority in chronic disease management. These converging factors are accelerating the adoption of innovative therapies, thereby significantly boosting the industry's growth

U.S. Arthritis Market Analysis

• Arthritis, encompassing conditions such as osteoarthritis, rheumatoid arthritis, and psoriatic arthritis, continues to pose a major public health burden in the U.S., with increasing patient volumes driving demand for advanced and personalized treatment solutions across both clinical and outpatient settings due to chronic pain, disability, and reduced quality of life
• The rising prevalence of arthritis is primarily driven by an aging population, increasing obesity rates, sedentary lifestyles, and improved awareness and diagnosis of joint-related disorders
• In 2024, the U.S. arthritis market was characterized by strong growth in biologics and targeted therapies, supported by a well-established healthcare infrastructure, high treatment accessibility, and continued innovation from pharmaceutical and biotechnology companies
• Demand for advanced options such as JAK inhibitors, biosimilars, and minimally invasive procedures is accelerating, particularly as patients and physicians seek longer-lasting, more effective interventions
• The osteoarthritis segment held the largest share of the U.S. arthritis market at 52.1% in 2024, propelled by its widespread prevalence in the aging population and growing emphasis on early intervention, lifestyle modification, and regenerative treatment approaches

Report Scope and U.S. Arthritis Market Segmentation

U.S. Arthritis Market Trends

“Shift Toward Biologics and Targeted Therapies”

• A significant and accelerating trend in the U.S. arthritis market is the transition from traditional anti-inflammatory treatments to biologics and targeted therapies such as JAK inhibitors and IL-6 blockers. These advanced therapeutics are delivering improved patient outcomes with better symptom management and disease modification
• For instance, AbbVie’s Humira and Rinvoq have gained widespread usage due to their targeted mechanisms and ability to treat multiple forms of arthritis, including rheumatoid arthritis and psoriatic arthritis. Similarly, Pfizer’s Xeljanz has been adopted for its JAK inhibition pathway, offering oral administration and efficacy in patients who do not respond to conventional treatments
• The adoption of these targeted therapies is supported by increasing physician preference for personalized treatment strategies and patient demand for more effective options with fewer side effects. Biologics can reduce disease activity, improve joint function, and slow structural damage, making them attractive choices for long-term management
• In addition, the rise in combination therapy—using biologics alongside methotrexate or NSAIDs—is gaining traction to improve efficacy and reduce flare-ups. Continued advancements in biomarker-driven diagnostics are also enabling early identification of patients who will benefit most from targeted drugs
• This trend toward precision medicine is reshaping arthritis treatment protocols across the U.S., driving investment in research and innovation by pharmaceutical leaders. As the number of FDA-approved biologics and biosimilars continues to rise, access is improving and costs are gradually declining, further encouraging widespread adoption
• The growing clinical emphasis on disease remission rather than just symptom control is pushing the market toward more aggressive, yet tailored, therapeutic approaches in both moderate and severe cases of arthritis

U.S. Arthritis Market Dynamics

Driver

“Rising Prevalence and Expanding Access to Advanced Treatments”

• The increasing prevalence of arthritis in the U.S., particularly among the aging population and those with comorbid conditions such as obesity and diabetes, is a key driver of market growth
• For instance, according to the CDC, nearly 60 million U.S. adults are expected to be diagnosed with some form of arthritis by 2040, underscoring the escalating demand for effective management solutions. In response, healthcare providers are expanding treatment programs and chronic care strategies tailored to long-term arthritis care
• Biologic and biosimilar therapies are becoming more accessible due to insurance coverage improvements, formulary inclusions, and patient assistance programs. Major players such as Johnson & Johnson, Amgen, and Eli Lilly are actively investing in U.S.-based trials and partnerships to expand market reach
• In addition, increasing public and private funding for arthritis research, combined with the availability of minimally invasive procedures, pain management interventions, and telehealth services, is making treatment more widely accessible across both urban and rural regions
• Growing awareness campaigns by organizations such as the Arthritis Foundation are also educating patients on early diagnosis and lifestyle changes, improving treatment outcomes and driving proactive healthcare engagement

Restraint/Challenge

“High Cost of Biologics and Access Inequality”

• Despite advances in treatment, the high cost of biologic drugs remains a significant barrier to broader adoption in the U.S. arthritis market. Some biologics can cost upwards of USD 30,000 annually, limiting access for uninsured patients or those with limited insurance coverage
• For instance, although biosimilars offer more affordable alternatives, pricing structures, patent disputes, and slow formulary acceptance continue to hinder their widespread usage in the U.S. healthcare system
• Reimbursement complexities and out-of-pocket expenses can discourage both patients and providers from opting for newer treatments, especially among economically disadvantaged populations or in areas with limited rheumatology care access
• Furthermore, long-term use of immunosuppressive therapies such as JAK inhibitors raises safety concerns related to infection risks and malignancy, leading to heightened regulatory scrutiny. The FDA has issued warnings on some products, requiring continuous monitoring and risk evaluation
• To overcome these challenges, expanding biosimilar adoption, improving healthcare equity, and driving policy changes aimed at reducing patient financial burden will be critical to ensure sustained growth and accessibility in the U.S. arthritis market

U.S. Arthritis Market Scope

The market is segmented on the basis of type, product, drug type, medication type, route of administration, population type, end user, and distribution channel.

• By Type

On the basis of type, the U.S. arthritis market is segmented into rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, spondyloarthritis, juvenile idiopathic arthritis (JIA), and others. The osteoarthritis segment dominated the market with the largest market revenue share of 52.1% in 2024, driven by its high prevalence among the elderly population and individuals with obesity and joint injuries. Osteoarthritis remains the most common form of arthritis in the U.S., with increasing demand for pain management and joint preservation therapies. The market also sees strong uptake of osteoarthritis treatments due to ongoing advancements in minimally invasive procedures and regenerative medicine approaches.

The psoriatic arthritis segment is anticipated to witness the fastest growth rate of 19.4% from 2025 to 2032, fueled by rising awareness, earlier diagnosis, and the expanding use of biologics. Improved access to targeted therapies and insurance coverage for chronic autoimmune conditions are further contributing to the growth of this segment across the U.S. market.

• By Product

On the basis of product, the U.S. arthritis market is segmented into treatment and diagnosis. The treatment segment held the largest market revenue share in 2024, driven by the widespread use of conventional DMARDs, biologics, corticosteroids, and pain relievers. The high patient volume requiring long-term treatment regimens contributes to consistent demand in this segment, supported by physician preference for evidence-based pharmacologic management.

The diagnosis segment is projected to grow significantly through 2032, due to increasing emphasis on early disease identification through imaging techniques, biomarker-based testing, and improved access to rheumatology consultations and diagnostic services.

• By Drug Type

On the basis of drug type, the U.S. arthritis market is segmented into branded and generics. The branded segment accounted for the largest market share in 2024 due to the clinical dominance of high-cost biologics such as Humira, Enbrel, and Xeljanz. These drugs are widely prescribed for moderate to severe cases, with robust clinical data and physician familiarity contributing to sustained revenue.

The generics segment is expected to register the fastest CAGR from 2025 to 2032, driven by increased cost-consciousness among healthcare payers and growing FDA approvals for biosimilars. Generic versions of DMARDs and NSAIDs are gaining traction due to their affordability and broad accessibility.

• By Medication Type

On the basis of medication type, the U.S. arthritis market is segmented into prescription drugs and over-the-counter (OTC) drugs. The prescription drugs segment dominated the market in 2024 due to the necessity of physician-prescribed biologics, immunosuppressants, and advanced therapies in moderate to severe cases of arthritis.

The OTC drugs segment is projected to grow steadily during the forecast period, driven by strong consumer demand for self-care options such as NSAIDs, topical analgesics, and supplements. Increased availability of arthritis pain relief products in retail and e-commerce channels supports this trend.

• By Route of Administration

On the basis of route of administration, the U.S. arthritis market is segmented into parenteral, oral, and others. The parenteral segment held the largest market revenue share in 2024, attributed to the dominance of injectable biologics and the growing availability of in-home infusion services.

The oral segment is expected to experience significant growth through 2032, supported by the increasing prescription of oral JAK inhibitors and conventional treatments that offer convenience and improved patient compliance compared to injectables.

• By Population Type

On the basis of population type, the U.S. arthritis market is segmented into geriatrics, adults, and children. The geriatrics segment accounted for the largest share in 2024, reflecting the high incidence of osteoarthritis and rheumatoid arthritis in aging individuals.

The adult segment is expected to show notable growth during the forecast period, fueled by the increasing diagnosis of autoimmune arthritis in younger adults and rising awareness of early treatment. The children segment, which includes juvenile idiopathic arthritis (JIA), continues to grow gradually, supported by pediatric rheumatology programs and approval of biologics for younger age groups.

• By End User

On the basis of end user, the U.S. arthritis market is segmented into hospitals, specialty centers, homecare, and others. The hospital segment led the market with the largest revenue share in 2024 due to the presence of multidisciplinary care teams and access to advanced diagnostic and therapeutic services.

The homecare segment is projected to witness the fastest growth rate during the forecast period, driven by the shift toward remote treatment, telehealth consultations, and self-administration of biologics. Specialty centers, including rheumatology clinics, also represent a growing segment due to patient preference for focused, streamlined arthritis care.

• By Distribution Channel

On the basis of distribution channel, the U.S. arthritis market is segmented into direct tender, retail sales, and others. The retail sales segment dominated the market in 2024, driven by widespread availability of arthritis medications in retail pharmacies and growing e-commerce penetration.

The direct tender segment, involving bulk procurement by hospitals and government institutions, remains a key channel for branded biologics and specialty medications. Other distribution channels, including specialty pharmacy services and mail-order delivery, are gaining traction for chronic arthritis treatment management.

U.S. Arthritis Market Share

The U.S. Arthritis industry is primarily led by well-established companies, including:

• AbbVie Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Amgen Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Lilly (U.S.)
• Bristol Myers Squibb Company (U.S.)
• Gilead Sciences, Inc. (U.S.)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• UCB S.A. (Belgium)
• Novartis AG (Switzerland)
• Roche Holding AG (Switzerland)
• Sanofi (France)
• Merck & Co., Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Boehringer Ingelheim International GmbH (Germany)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Horizon Therapeutics plc (Ireland)
• AstraZeneca (U.K.)
• Sandoz Group AG (Switzerland)
• Viatris Inc. (U.S.)

What are the Recent Developments in U.S. Arthritis Market?

• In March 2024, AbbVie Inc., a global leader in immunology, announced the U.S. FDA approval of Rinvoq (upadacitinib) for the treatment of non-radiographic axial spondyloarthritis. This approval expands the drug’s label and reflects AbbVie’s ongoing commitment to developing targeted therapies for a wide range of arthritis-related conditions. By providing new treatment options for previously underserved patient populations, AbbVie continues to strengthen its leadership in the U.S. arthritis therapeutics landscape
• In February 2024, Pfizer Inc. launched an expanded patient support program for its rheumatoid arthritis drug Xeljanz in the U.S., aimed at improving treatment adherence and affordability. The program includes co-pay assistance, remote nurse support, and educational tools, highlighting Pfizer’s patient-centric approach to chronic disease management and its focus on enhancing the treatment experience in real-world settings
• In January 2024, Amgen Inc. reported positive Phase 3 clinical trial results for its investigational biosimilar to adalimumab (a reference to Humira), signaling a key step toward broader access and cost reduction for U.S. arthritis patients. The biosimilar demonstrated comparable efficacy and safety, supporting Amgen’s strategy to strengthen its presence in the growing biosimilars segment of the arthritis market
• In December 2023, Johnson & Johnson’s Janssen division launched a new awareness campaign titled “Move Without Pain” across major U.S. cities, promoting early diagnosis and advanced treatment options for psoriatic arthritis. The initiative, involving healthcare professionals and patient influencers, aims to reduce diagnosis delays and promote the role of biologics and targeted therapies in long-term disease management
• In November 2023, Eli Lilly and Company received U.S. FDA fast track designation for its investigational monoclonal antibody therapy targeting interleukin-17 in patients with active ankylosing spondylitis. This regulatory milestone underscores Lilly’s commitment to expanding its immunology portfolio and addressing unmet needs within the arthritis community through precision medicine and accelerated innovation

SKU-68043